Related Experiment Videos
Pre-clinical evaluation of a novel chloroethylating agent, Clomesone
A M Matthew1, R M Phillips, P M Loadman
1Clinical Oncology Unit, University of Bradford, West Yorkshire, UK.
Abstract:
The in vitro activity of the novel chloroethylating agent, Clomesone, was investigated in a panel of established murine and human tumour cell lines. In vivo anti-tumour activity was examined against three transplantable adenocarcinomas of the mouse colon and in vivo bone marrow toxicity was assessed using a spleen colony forming unit assay. The pharmacokinetic behaviour of the drug in vivo and drug stability in vitro was analysed by gas chromatography with electron capture detection. Clomesone exhibited no activity in vitro against the majority of cell lines derived from solid human colorectal carcinomas. Anti-tumour activity against the murine tumours in vivo was not impressive and was accompanied by myelosuppression. Pharmacokinetic data suggested that the lack of in vivo activity was due to the failure to achieve effective anti-neoplastic drug concentrations at the tumour site. It was concluded that this study found no evidence to suggest that Clomesone was toxicologically more selective than the chloroethylnitrosoureas.
Insights
Clomesone, a novel chloroethylating agent, showed limited anti-cancer activity in vitro and in vivo. Its poor pharmacokinetic profile prevented effective anti-neoplastic concentrations, indicating no significant toxicological advantage over existing agents.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Novel chloroethylating agents are explored for cancer therapy.
- Clomesone is a new agent with potential anti-tumour properties.
Purpose of the Study:
- To evaluate the in vitro and in vivo anti-tumour activity of Clomesone.
- To assess its toxicity and pharmacokinetic profile.
- To compare its selectivity with chloroethylnitrosoureas.
Main Methods:
- In vitro cytotoxicity testing against human and murine tumor cell lines.
- In vivo anti-tumour efficacy assessment in mouse colon adenocarcinoma models.
- Bone marrow toxicity evaluation using spleen colony forming unit assay.
- Pharmacokinetic analysis and in vitro drug stability determination via gas chromatography.
Main Results:
- Clomesone demonstrated minimal in vitro activity against colorectal carcinoma cell lines.
- In vivo anti-tumour effects against murine tumors were modest and associated with myelosuppression.
- Pharmacokinetic data indicated insufficient drug concentrations at the tumor site.
- Clomesone did not show greater toxicological selectivity compared to chloroethylnitrosoureas.
Conclusions:
- Clomesone lacks significant in vitro and in vivo anti-cancer efficacy.
- Poor pharmacokinetics limit its therapeutic potential.
- The drug offers no apparent toxicological advantage over established chloroethylnitrosoureas.